|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Occult hepatitis B virus infection among Egyptian blood donors显示文摘AIM:To identify blood donors with occult hepatitis B virus(HBV) infection(OBI) to promote safe blood donation.METHODS:Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen(HBsAg),hepatitis C antibody(HCV Ab) and human immunodeficiency virus Ab.They were subjected to the detection of alanine aminotransferase(ALT) and aspartate transaminase(AST) and screening for anti-HBV core antibodies(total) by two different techniques;[Monoliza antibodies to hepatitis B core(Anti-HBc) Plus-Bio-Rad] and(ARC-HBc total-ABBOT).Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface(anti-HBs)(ETI-AB-AUK-3,Dia Sorin-Italy).Serum anti-HBs titers > 10 IU/L was considered positive.Quantitative HBV DNA by real time polymerase chain reaction(PCR)(QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L.Also,265 recipients were included,34 of whom were followed up for 3-6 mo.Recipients were investigated for ALT and AST,HBV serological markers:HBsAg(ETI-MAK-4,Dia Sorin-Italy),anti-HBc,quantitative detection of anti-HBs and HBV-DNA.RESULTS:525/3167(16.6%) of blood units were positive for total anti-HBc,64% of those were antiHBs positive.Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples,where 451(90.6%) confirmed positive.Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample,giving an overall prevalence of 451/3167(14.2%) for total anti-HBc.HBV DNA was quantified by real time PCR in 52/303(17.2%) of anti-HBc positive blood donors(viral load range:5 to 3.5 x 105 IU/mL) with a median of 200 IU/mL(mean:1.8 x 104 ± 5.1 x 104 IU/mL).AntiHBc was the only marker in 68.6% of donors.Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8(1.4-2.4) and 1.4(1.0-1.9) respectively.Other risk factors as gender,history of blood transfusion,diabetes mellitus,frequent injections,tattooing,previous surgery,hospitalization,Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies.Among anti-HBc positive blood donors,age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8(1.8-7.9).According to HBV-DNA concentration,positive samples were divided in two groups;group one with HBV-DNA ≥ 200 IU/mL(n = 27) and group two with HBV-DNA < 200 IU/mL(n = 26).No significant difference was detected between both groups as regards mean age,gender,liver enzymes or HBV markers.Serological profiles of all followed up blood recipients showed that,all were negative for the studied HBV markers.Also,HBV DNA was not detected among studied recipients,none developed post-transfusion hepatitis(PTH) and the clinical outcome was good.CONCLUSION:OBI is prevalent among blood donors.Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation. | Zeinab N Said Manal H El Sayed Iman I Salama Enas K Aboel-Magd Magda H Mahmoud Maged El Setouhy Faten Mouftah Manal B Azzab Heidi Goubran Amal Bassili Gamal E Esmat | 2013 | World Journal of Hepatology2013，5，2： | 4 |
| 2 | Robust voice activity detection using higher-order statistics in the LPC residual domain 显示文摘 | NEMER E GOUBRAN R MAHMOUD S | 2001 | Speech and Audio Processing2001，9，3： | 1 |
| 3 | Fibrin sealant: scientific rationale, production methods, properties, and current clinical use 显示文摘 | Radosevich M Goubran HA Burnouf T | 1997 | Vox Sang1997，72，： | 1 |
| 4 | Blood-derived biomaterials and platelet growth factors in regenerative medicine显示文摘 | Burnouf T Goubran HA Chen TM | | 0，，02： | 1 |
| 5 | Effects of storage time and leuco- cyte burden of packed and buffy-coat depleted red blood cell units on red cell storage Lesion 显示文摘 | Kamel N Goubran F Ramsis N | 2010 | Blood Transfus2010，8，4： | 1 |
| 6 | Platelet mieroparticles : detection and assessment of their paradoxical functional roles in disease and regenerative medicine 显示文摘 | Bumouf T Goubran HA Chou ML | 2014 | Blood Rev2014，28，4： | 1 |
| 7 | Fribin sealant:scientific rationale,production methods,properties,and current clinical use显示文摘 | Radosevich M Goubran HI Burnouf T | 1997 | Vox Sang1997，72，3： | 1 |
| 8 | A H Experimental signal analysis in ion mobility spectrometry 显示文摘 | Goubran R A Lawrence | 1991 | International Journal of Mass Spectrometry and Ion Process1991，104，： | 1 |
| 9 | Speech enhancement using a masking threshold constrained Kalman filter and its heuristic implementations显示文摘 | Ma Ning Bouchard M Goubran R A | 2006 | IEEE Trans on Audio Speech and Language Processing2006，14，1： | 1 |
| 10 | Abnormal melatonin synthesis in autism spectrum disorders显示文摘 | Melke J Goubran B H Chaste P | 2008 | Mol Psychiatry2008，13，1： | 1 |
| 11 | Security monitoring using microphone arrays and audio classifica- tion显示文摘 | Abu ei-quran A R Goubran R A Chan A D C | 2006 | IEEE Trans Instrumental and Measurements2006，55，4： | 1 |
| 12 | Fibrin sealant: scientific rationale, production methods, properties, and current clinical use 显示文摘 | Radosevich M Goubran HI Burnouf T | 1997 | Vox Sang1997，72，3： | 1 |
| 13 | Fibrin sealant: scientific rationale, production methods, properties, and current clinical use 显示文摘 | RADOSEVICH M GOUBRAN H I BURNOUF T | 1997 | Vox Sang1997，72，3： | 1 |
| 14 | The platelet-cancer loop显示文摘 | Goubran H Burnouf T Radosevic M | 2013 | Eur J Int Med2013，24，5： | 1 |
| 15 | Fibrin sealant: scientific rationale,production methods, properties and current clinical use显示文摘 | Radosevich M Goubran HA | 1997 | Vox Sang1997，72，3： | 1 |
| 16 | Fibrin sealant: scientific rationale, production methods, properties, and cur rent clinical use显示文摘 | Radosevich M Goubran HI Burnouf | 1997 | Vox Sang1997，72，3： | 1 |
| 17 | Fibrin sealant:scientific rationale,production methods,roperties,and current clinical use显示文摘 | Radosevich M Goubran HA | 1997 | Vox Sang1997，72，4： | 1 |
| 18 | Discrete cosine transformparticle filter speech enhancement显示文摘 | Laska B Boli? M Goubran R | 2010 | Speech Communication2010，52，9： | 1 |
| 19 | Robust Voice Activity Detection Using Higher-order Statistics in the LPC Residual Domain显示文摘 | Nemer E Goubran R Mahmoud S | 2001 | IEEE Trans on Speech and Audio Processing2001，9，3： | 1 |
| 20 | Fibrin sealant:scientific rationale,production methods,properties,and current clinical use显示文摘 | Radosevich M Goubran HI Burnouf T | 1997 | Vox Sang1997，72，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员